Heron (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics reported Q1 net sales of $34.7 million and reaffirmed full-year 2026 guidance of $173 million to $183 million in net product sales and $10 million to $20 million in adjusted EBITDA. Results were held back by two weeks of severe weather and temporary gross margin pressure from higher-cost CINVANTI batches, which pushed adjusted EBITDA to a loss of $727,000, but March sales rebounded above $15 million. Commercially, ZYNRELEF demand rose 22% year over year, APONVIE demand units grew 68%, and CINVANTI held a stable 25% exit share, with management highlighting reimbursement tailwinds and a planned Q3 sales force expansion.

Analysis

The market is likely to underwrite the quarter as weather noise, but the more important signal is that Heron is getting multiple independent growth engines to compound at once: reimbursement simplification, form payload expansion, and a broader field-force footprint. That matters because this business is now less dependent on one-off stocking behavior and more on repeat institutional protocol adoption, which tends to create a lagged but stickier revenue slope into the back half of the year.

The second-order effect is that the guidance looks conservative if surgical volumes normalize and if the newly formalized account wins convert on schedule. ZYNRELEF appears to be benefiting from a self-reinforcing loop: cleaner reimbursement reduces administrative friction, which improves conversion, which justifies more distributor attention, which in turn supports broader surgeon-level usage inside existing accounts. APONVIE may be the bigger hidden upside because guideline endorsement can change formulary behavior faster than pure sales effort, especially in higher-risk procedures where anesthesiology protocols are standardized.

The main bear case is that the business still has operating leverage in both directions: a modest revenue miss or another quarter of margin drag can quickly pressure EBITDA given the company’s size. The gross margin issue is transitory, but the Street may be skeptical until it sees two clean quarters and proof that demand acceleration survives outside the post-storm rebound. The real catalyst window is Q2/Q3: if account adds and sales-force expansion translate into visible sequential growth before the margin normalization fully arrives, the stock should re-rate as a credible self-funded growth story rather than a weather-recovery trade.

Key Decisions for Investors

• Long HRTX on a 3-6 month horizon into Q2/Q3 commercial inflection; use pullbacks after any post-earnings fade to build. Risk/reward skews favorably if management proves sequential sales re-acceleration and gross margin normalization; downside is limited by reaffirmed full-year guide, but execution risk remains meaningful.
• Buy HRTX July/Aug 2026 call spreads to express a high-conviction rebound in elective procedures and account conversion. Target a structure that pays if the market starts pricing 2H sales acceleration before margin normalization is fully visible.
• Pair trade: long HRTX / short BAX for the next 1-2 quarters. The thesis is that Heron has cleaner near-term operating catalysts, while Baxter-linked uncertainty around the settlement overhang is harder to underwrite; this isolates product adoption momentum versus legal/event risk.
• If already long HRTX, hedge with short-dated put protection into the next earnings date. The stock is vulnerable to any delay in the March recovery flowing through to Q2, and the small-cap biotech tape can punish even modest EBITDA misses.
• Watch for confirmation from APONVIE account growth and ZYNRELEF ordering-account expansion before adding aggressively. If either stalls for two reporting periods, trim exposure because the bull case depends on protocol adoption, not just weather rebound.